摘要
目的对比分析应用雷米普利治疗2型糖尿病肾病患者对不同时期蛋白尿的降低作用。方法选取2013年4月~2016年4月期间我院收治2型糖尿病肾病患者194例,按照就诊ID号随机分为观察组与对照组两组,对照组患者接受厄贝沙坦治疗,观察组患者接受雷米普利治疗,比较两组患者治疗前后24h尿蛋白定量、白蛋白水平以及尿细胞数量。结果经过3个月治疗后,所有各期患者24h尿蛋白定量、白蛋白水平以及尿细胞数量较治疗前均下降,具有统计学差异(P<0.05);组间24h尿蛋白定量水平比较,观察组各期患者总蛋白水平均优于对照组各期患者,差异显著(P<0.05);尿细胞数量比较,观察组尿足细胞数量明显低于对照组,具有统计学差异(P<0.05)。结论应用雷米普利治疗2型糖尿病肾病患者疗效确切,可有效降低24h尿蛋白定量、白蛋白水平,减少足细胞脱落、保护肾功能,可在临床治疗中推广应用。
Objective To analyze the reduction effect of ramipril on albuminuria of type 2 Diabetic Nephropathy patients in different pririod. Methods 194 patients with type 2 diabetic nephropathy cured in our hospital from April 2013 to April 2016 were selected and randomly divided into control group and observation group according to ID number. Patients in control group were treated with irbesartan, and patients in the observation group were treated with ramipril. The changes of urinary total protein, albumin and urinary podocyte numbers were compared. Results The urinary total protein and albumin levels after treatment were significantly better than that before treatment（P 〈 0.05）, and it showed significant difference between the two groups （P 〈 0.05）. The urinary podocyte numbers of observation group were significantly lower than that of control group （P 〈 0.05）. Conclusion The ramipril is effective for patients with type 2 diabetic nephropathy. It can reduce urinary total protein and albumin levels, reduce the loss ofurinary podocyte, and protect renal function. It has a further application in clinical treatment.
出处
《中国医药科学》
2017年第1期78-80,共3页
China Medicine And Pharmacy
